Table 3 Open in new tab Outcomes a in...

	Timely pPCI (≤120 min)	Delayed pPCI (121–180 min)	Late pPCI (>180 min)	P-I strategy
Death	742 (10.3%)	1.3 (1.1–1.5)	1.1 (1.0–1.3)	224 (14.6%)	1.9 (1.5–2.3)	1.3 (1.0–1.5)	157 (15.5%)	2.1 (1.6–2.5)	1.4 (1.1–1.7)	205 (8.9%)
Composite endpoint (death, non-fatal stroke, and non-fatal MI)	1015 (14.0%)	1.1 (1.0–1.2)	1.0 (0.9–1.2)	290 (18.9%)	1.5 (1.3–1.8)	1.2 (1.0–1.4)	206 (20.4%)	1.7 (1.4–2.0)	1.3 (1.1–1.5)	320 (13.7%)

Timely pPCI (≤120 min)

Delayed pPCI (121–180 min)

Late pPCI (>180 min)

P-I strategy

n = 7238

n = 1537

n = 1012

n = 2338

Hazard ratio (95% CI)^b

Adjusted HR (95% CI)^b^,c

Hazard ratio (95% CI)^b

Adjusted HR (95% CI)^b^,c

Hazard ratio (95% CI)^b

Adjusted HR (95% CI)^b^,c

Death

742 (10.3%)

1.3 (1.1–1.5)

1.1 (1.0–1.3)

224 (14.6%)

1.9 (1.5–2.3)

1.3 (1.0–1.5)

157 (15.5%)

2.1 (1.6–2.5)

1.4 (1.1–1.7)

205 (8.9%)

Composite endpoint (death, non-fatal stroke, and non-fatal MI)

1015 (14.0%)

1.1 (1.0–1.2)

1.0 (0.9–1.2)

290 (18.9%)

1.5 (1.3–1.8)

1.2 (1.0–1.4)

206 (20.4%)

1.7 (1.4–2.0)

1.3 (1.1–1.5)

320 (13.7%)

	Timely pPCI (≤120 min)	Delayed pPCI (121–180 min)	Late pPCI (>180 min)	P-I strategy
Death	742 (10.3%)	1.3 (1.1–1.5)	1.1 (1.0–1.3)	224 (14.6%)	1.9 (1.5–2.3)	1.3 (1.0–1.5)	157 (15.5%)	2.1 (1.6–2.5)	1.4 (1.1–1.7)	205 (8.9%)
Composite endpoint (death, non-fatal stroke, and non-fatal MI)	1015 (14.0%)	1.1 (1.0–1.2)	1.0 (0.9–1.2)	290 (18.9%)	1.5 (1.3–1.8)	1.2 (1.0–1.4)	206 (20.4%)	1.7 (1.4–2.0)	1.3 (1.1–1.5)	320 (13.7%)

Table 3

Open in new tab

Outcomes^a in patients with ST-elevation myocardial infarction receiving timely, delayed, and late pPCI compared to P-I strategy, Norway 2013–2019

	Timely pPCI (≤120 min)			Delayed pPCI (121–180 min)			Late pPCI (>180 min)			P-I strategy
	n = 7238			n = 1537			n = 1012			n = 2338
	n	Hazard ratio (95% CI)^b	Adjusted HR (95% CI)^b^,c	n	Hazard ratio (95% CI)^b	Adjusted HR (95% CI)^b^,c	n	Hazard ratio (95% CI)^b	Adjusted HR (95% CI)^b^,c	n
Death	742 (10.3%)	1.3 (1.1–1.5)	1.1 (1.0–1.3)	224 (14.6%)	1.9 (1.5–2.3)	1.3 (1.0–1.5)	157 (15.5%)	2.1 (1.6–2.5)	1.4 (1.1–1.7)	205 (8.9%)
Composite endpoint (death, non-fatal stroke, and non-fatal MI)	1015 (14.0%)	1.1 (1.0–1.2)	1.0 (0.9–1.2)	290 (18.9%)	1.5 (1.3–1.8)	1.2 (1.0–1.4)	206 (20.4%)	1.7 (1.4–2.0)	1.3 (1.1–1.5)	320 (13.7%)

	Timely pPCI (≤120 min)			Delayed pPCI (121–180 min)			Late pPCI (>180 min)			P-I strategy
	n = 7238			n = 1537			n = 1012			n = 2338
	n	Hazard ratio (95% CI)^b	Adjusted HR (95% CI)^b^,c	n	Hazard ratio (95% CI)^b	Adjusted HR (95% CI)^b^,c	n	Hazard ratio (95% CI)^b	Adjusted HR (95% CI)^b^,c	n
Death	742 (10.3%)	1.3 (1.1–1.5)	1.1 (1.0–1.3)	224 (14.6%)	1.9 (1.5–2.3)	1.3 (1.0–1.5)	157 (15.5%)	2.1 (1.6–2.5)	1.4 (1.1–1.7)	205 (8.9%)
Composite endpoint (death, non-fatal stroke, and non-fatal MI)	1015 (14.0%)	1.1 (1.0–1.2)	1.0 (0.9–1.2)	290 (18.9%)	1.5 (1.3–1.8)	1.2 (1.0–1.4)	206 (20.4%)	1.7 (1.4–2.0)	1.3 (1.1–1.5)	320 (13.7%)

Follow-up to 31 December 2019. Death: median follow-up 944 days (25th–75th percentile 396–1583). Composite endpoint: median follow-up 913 days (25th–75th percentile 335–1522).

Reference: Pharmaco-invasive (P-I) strategy.

Gender, age, smoking, previous stroke, previous AMI, history of heart failure, diabetes, antihypertensive treatment, renal failure (eGFR < 60 mL/min), and out-of-hospital cardiac arrest.

P-I strategy, pharmaco-invasive strategy; pPCI, primary percutaneous coronary intervention.

This Feature Is Available To Subscribers Only